SCHEMBL6718609

SCHEMBL6718609

Cc1ccc(-c2noc(CO)c2-c2ccc(S(C)(=O)=O)c(F)c2)cc1OC(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.39
PTGS2 P35354 4/20 0.37
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GRM2 Q14416 3/20 0.34
PAX8 Q06710 1/20 0.34
NR1H2 P55055 1/20 0.33
PIK3CD O00329 2/20 0.33
PIK3CA P42336 2/20 0.33
PIK3CB P42338 2/20 0.33
PIK3CG P48736 2/20 0.33
SYK P43405 1/20 0.33
PTGS1 P23219 1/20 0.32
PDE3A Q14432 1/20 0.32
GPR119 Q8TDV5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723328 0.93 PTGS2 (0.37) BRD4PTGS2MEN1NPC1KMT2A
SCHEMBL6718904 0.92 PTGS2 (0.43) BRD4PTGS2MEN1NPC1KMT2A
SCHEMBL6729549 0.92 PTGS2 (0.39) PTGS2MEN1NPC1KMT2AATM
SCHEMBL6741330 0.90 PTGS2 (0.38) BRD4PTGS2MEN1NPC1KMT2A
SCHEMBL6737089 0.89 BRD4 (0.36) BRD4PTGS2MEN1NPC1KMT2A
SCHEMBL6718900 0.88 PAX8 (0.46) BRD4PTGS2MEN1NPC1KMT2A
SCHEMBL6729415 0.87 BRD4 (0.44) BRD4PTGS2PIK3CDPIK3CAPIK3CB
SCHEMBL6722266 0.87 PTGS2 (0.42) PTGS2NR1H2PTGS1PDE3A
SCHEMBL6723362 0.86 BRD4 (0.44) BRD4PTGS2PIK3CDPIK3CAPIK3CB
SCHEMBL6722074 0.86 PTGS2 (0.48) PTGS2MEN1NPC1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 BRD4 384/4885PTGS2 5/4885MEN1 4391/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 BRD4 340/4885PTGS2 5/4885MEN1 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.